Your browser doesn't support javascript.
loading
Pathologic response and surgical outcomes in patients undergoing nephrectomy following receipt of immune checkpoint inhibitors for renal cell carcinoma.
Singla, Nirmish; Elias, Roy; Ghandour, Rashed A; Freifeld, Yuval; Bowman, Isaac A; Rapoport, Leonid; Enikeev, Mikhail; Lohrey, Jay; Woldu, Solomon L; Gahan, Jeffrey C; Bagrodia, Aditya; Brugarolas, James; Hammers, Hans J; Margulis, Vitaly.
Affiliation
  • Singla N; Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX.
  • Elias R; Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX.
  • Ghandour RA; Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX.
  • Freifeld Y; Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX.
  • Bowman IA; Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX.
  • Rapoport L; Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia.
  • Enikeev M; Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia.
  • Lohrey J; Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX.
  • Woldu SL; Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX.
  • Gahan JC; Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX.
  • Bagrodia A; Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX.
  • Brugarolas J; Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX.
  • Hammers HJ; Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX.
  • Margulis V; Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX. Electronic address: vitaly.margulis@utsouthwestern.edu.
Urol Oncol ; 37(12): 924-931, 2019 12.
Article de En | MEDLINE | ID: mdl-31522865
ABSTRACT

OBJECTIVE:

To evaluate the pathologic response, safety, and feasibility of nephrectomy following receipt of immune checkpoint inhibition (ICI) for renal cell carcinoma (RCC).

METHODS:

Patients who underwent nephrectomy for RCC after exposure to nivolumab monotherapy or combination ipilimumab/nivolumab were reviewed. Primary surgical outcomes included operative time (OT), estimated blood loss (EBL), length of stay (LOS), readmission rates, and complication rates. Pathologic response in the primary and metastatic sites constituted secondary outcomes.

RESULTS:

Eleven nephrectomies (10 radical, 1 partial) were performed in 10 patients after ICI with median postoperative follow-up 180 days. Six patients received 1 to 4 cycles of ipilimumab/nivolumab, while 5 received 2 to 12 infusions of nivolumab preoperatively. Five surgeries were performed laparoscopically, and 4 patients underwent concomitant thrombectomy. One patient exhibited complete response (pT0) to ICI, and 3/4 patients who underwent metastasectomy for hepatic, pulmonary, or adrenal lesions exhibited no detectable malignancy in any of the metastases resected. No patients experienced any major intraoperative complications, and all surgical margins were negative. Median OT, EBL, and LOS were 180 minutes, 100 ml, and 4 days, respectively. Four patients experienced a complication, including 3 that were addressed with interventional radiology procedures. One patient died of progressive disease >3 months after surgery, and 1 patient succumbed to pulmonary embolism complicated by sepsis. No complications or readmissions were noted in 6 patients.

CONCLUSION:

Nephrectomy following ICI for RCC is safe and technically feasible with favorable surgical outcomes and pathologic response. Timing of the nephrectomy relative to checkpoint dosing did not seem to impact outcome. Biopsies of lesions responding radiographically to ICI may warrant attention prior to surgical excision.
Sujet(s)
Mots clés

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Néphrocarcinome / Protocoles de polychimiothérapie antinéoplasique / Traitement néoadjuvant / Antinéoplasiques immunologiques / Tumeurs du rein / Néphrectomie Type d'étude: Observational_studies / Risk_factors_studies Limites: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Langue: En Journal: Urol Oncol Sujet du journal: NEOPLASIAS / UROLOGIA Année: 2019 Type de document: Article

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Néphrocarcinome / Protocoles de polychimiothérapie antinéoplasique / Traitement néoadjuvant / Antinéoplasiques immunologiques / Tumeurs du rein / Néphrectomie Type d'étude: Observational_studies / Risk_factors_studies Limites: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Langue: En Journal: Urol Oncol Sujet du journal: NEOPLASIAS / UROLOGIA Année: 2019 Type de document: Article